Zymedyne Therapeutics wins Macquarie University Incubator annual Pitch Final award for Most Valuable Investment 2023
From Macquarie Incubator: “Last week, we held our annual Pitch Final event for 2023! 🧠We had five startups that delivered excellent pitches: Stopfalls Physio Pty Ltd, Trappi, Lagvelki, Zymedyne Therapeutics and Loop Hydrometallurgy, with three winning the night’s top prizes! Congratulations to our winners: Dave Sammut from Loop Hydrometallurgy won Best Pitch, receiving $3,000! Dr Chris Bladen from Zymedyne Therapeutics won Most Valuable Investment, receiving $5,000! Last but not least, Anna Stackpool from Stopfalls Physio Pty Ltd won the Researchers Engagement award, receiving $25,000 to put towards Macquarie University researchers and HDR students to validate, review and/or conduct commercial research activities! We want to thank our MC, Alistair Booth for helping us run the event, and our judges, Matthew Edmonds, Alan Jones, Jessica Baird Walsh, and Dan Geaves FFIA, who provided their time to listen to our startups pitch and ultimately make a tough decision on the winners. We’d…
Award For Outstanding Innovation – Dr. Ketul Patel
Zymedyne Therapeutics is extremely proud of our Medicinal Chemist Ketulbhai Patel for winning the 2023 Mitacs Award for Outstanding Innovation. Ketul is a brilliant chemist and key part of Zymedyne’s team and thoroughly deserves the national recognition of this award. Zymedyne is also very grateful to the support we receive from Mitacs and hope to continue building the positive partnership we have with them and help grow Canada’s Biotechnology globally! From Mitacs: Prestigious Mitacs Awards Celebrate Canada’s Top Innovators – Mitacs
AZ/NZ TMRRW Award Winner
Zymedyne is pleased to announce that we have won the #Challenger Award in the #Innovation Category at the 2023 Australia New Zealand TMMRW Awards! Click to view the post below: https://www.linkedin.com/posts/connectmpid_macquariepark-ugcPost-7135434121287254016-5c9T?utm_source=share&utm_medium=member_desktop
SXSW Sydney Pitch Competiton: 1st Place Award
Zymedyne Therapeutics wins 1st place in the SXSW Sydney pitch competition in the Healthcare, Biotech, Future of Medicine, category. Chris Bladen posted on LinkedIn
Campus Alberta Neuroscience Spotlight
Zymedyne is pleased to announce a spotlight on the Campus Alberta Neuroscience LinkedIn page! From Campus Alberta: “What would you think about an effective pain relief solution that doesn’t cause weight gain, respiratory depression, or addiction? Zymedyne Therapeutics is working on a technology to do just that” View post: https://www.linkedin.com/posts/campus-alberta-neuroscience_zymedyne-therapeutics-activity-6996577577083555841-AyaH?utm_source=li_share&utm_content=feedcontent&utm_medium=g_dt_web&utm_campaign=copy
TENET i2c Competition at #inventures2022, (1st prize: $10,000)
Zymedyne would like to congratulate CEO Chris Bladen on winning the “Engineering solutions for human and animal health” TENET i2c Competition at #inventures2022, (1st prize: $10,000)
LIBI Podcast Supported by Rainforest Alberta
Peter Beaudoin Hosts Zymedyne CEO & Co-founder on the Leaders, Innovators & Big Ideas (LIBI) podcast. To listen, visit: https://www.podbean.com/ew/pb-b7h2f-11b0817
Zymedyne ACS Chemical Neuroscience Publication
Zymedyne is excited to report some of their groundbreaking research in the leading Journal ACS Chemical Neuroscience! Link to publication: https://pubs.acs.org/doi/10.1021/acschemneuro.1c00765?ref=pdf
Mitacs Accelerate Industrial Postdoc awarded to Dr. Ketul Patel, Zymedyne’s PostDoc Organic Chemist
Zymedyne Therapeutics is pleased to announce that a Mitacs Accelerate Industrial Postdoc has been awarded to Dr Ketul Patel to conduct structure-activity relationship studies and assess the molecular properties of Zymedyne’s lead molecules. Using organic synthesis and medicinal chemistry, Ketul’s work will also help develop new drugs with improved potency, specificity, and commercial potential. The Mitacs Accelerate Industrial Postdoc, together with the partnering company, provides up to three years of funding – valued at up to $60,000 per year. For more information, please visit: https://www.mitacs.ca/en/programs/accelerate/industrial-postdoc
Zymedyne Therapeutics awarded 1st place in the EntrepreNeuro Pitch Competition from Campus Alberta Neuroscience.
Zymedyne is pleased to announce that Co-founder Dr. Chris Bladen was awarded 1st place in the “EntrepreNeuro Pitch Competition” from Campus Alberta (CAN). The CAN “Entrepeneuro” Program is a 7-week cohort-based program designed to support early-stage neuroscience projects to launch or grow their innovations. The prize money awarded will help Zymedyne with patenting costs associated with developing our novel non-opioid-based pain therapeutics platform. To learn more about the CAN Entrepreneuro program, visit: https://www.albertaneuro.ca/entrepreneuro/